UroGen Pharma Ltd. (NASDAQ:URGN) headquartered in New York, will host a conference call for the investment community to discuss the 2Q20 earnings result on 10th August 2020 at 8:30 AM Eastern Time.
Those interested in listening to the conference call live via the Internet can visit www.urogen.com
Earnings Expectation
UroGen Pharma Ltd. is expected to report second quarter earnings results, before market open, on Monday 10th August 2020. Analysts polled by Thomson Reuters anticipate second quarter loss of $ 1.58 per share from revenue of $ 0.26 million. Looking ahead, the full year loss are expected at $ 6.23 per share on the revenues of $ 12.55 million.
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The companys lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer.
